Human immunodeficiency virus protease inhibitors (Q45751680)

15 December 2017

review article

1 reference

title

Human immunodeficiency virus protease inhibitors (English)

1 reference

15 December 2017

author name string

Rana KZ

series ordinal

1

1 reference

15 December 2017

Dudley MN

series ordinal

2

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

15 December 2017

published in

Pharmacotherapy

1 reference

15 December 2017

volume

19

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

35-59

1 reference

15 December 2017

Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Therapy for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

The HIV-1 protease as a therapeutic target for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Complete nucleotide sequence of the AIDS virus, HTLV-III

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

A structural model for the retroviral proteases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Inhibitors of aspartyl proteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Inhibition of the renin-angiotensinogen reaction by pepstatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

HIV-proteinase inhibitors in the management of HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Drug interactions in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Substrates of human hepatic cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Molecular mechanisms of antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Retroviral protease-like sequence in the yeast transposon Ty 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Renin inhibition by pepstatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

Safety and activity of saquinavir in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.35.30513

10.1592/PHCO.19.1.35.30513

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

9917077

1 reference

15 December 2017